Wound care real world data (RWD) is information on patients, products, and outcomes generated outside randomized controlled trials, and it now carries much of the evidentiary load in a field where RCTs are few, short, and narrow. It supports coverage arguments, post-market clinical follow-up (PMCF), and competitive strategy, but only when the dataset matches the question being asked. A large dataset with the wrong setting mix, undefined healing endpoints, or no patient-level detail can look authoritative and still fail under scrutiny from a payer, a notified body, or an auditor.
The useful question is therefore not whether RWD is good evidence, but what a specific source can credibly support and where it breaks. The sections below cover the main sources, what they capture and miss, how they are used, and how to test fitness for purpose before you rely on one.
Why Is Real World Data Central to Wound Care Evidence?
The RCT base in chronic wounds is constrained by design. Pivotal trials in DFU and VLU typically enroll patients who meet tight criteria on wound size, duration, perfusion, infection status, and comorbidity control, and they often run for a fixed treatment window of around 12 weeks. FDA’s guidance on developing products for chronic cutaneous ulcers and burns frames complete wound closure as the key endpoint, which pushes trial design toward that kind of bounded observation. Comparators are usually a protocolized standard of care, which is more uniform than what patients receive in routine practice.
That produces a mismatch with real use. A CTP or CAMP may be studied in a hospital-based wound center with weekly debridement and strict offloading, then applied largely in skilled nursing facilities or home visits, where visit frequency, offloading adherence, and documentation differ. Practice variation across those settings means trial populations often do not resemble the patients and wounds where products are actually used. Effect sizes measured under controlled conditions do not transfer automatically.
Regulatory and payer pressure raises the stakes. Medicare skin substitute coverage has been in flux, with local coverage determinations (LCDs) from several MACs setting evidence expectations and CMS payment policy changing how these products are reimbursed. As of November 2026, you should confirm the current LCD status, effective dates, and any payment rule changes directly with CMS and the relevant MAC before building a strategy on them, because both have shifted repeatedly. Whatever the final form, the direction is consistent: payers want evidence tied to defined wound types and outcomes. In the EU, medical device manufacturers carry PMCF obligations under MDR that require continuing collection of clinical data after launch.
Both pressures create demand for post-market evidence that reflects routine care. RWD is the only practical way to produce it at scale, which is why its limits matter as much as its availability.
Where Does Wound Care Real World Data Come From?
Four source types dominate, and each answers different questions.
- EHR and wound-specific documentation platforms. These hold the clinical detail: wound dimensions, tissue type, exudate, treatment orders, and visit dates. Quality depends on how consistently clinicians chart. Free-text notes and inconsistent measurement technique are common, and structured fields vary across vendors.
- Claims data (Medicare FFS, commercial). Claims show what was billed, when, by whom, and at what cost, across very large populations. They do not record wound area, depth, or healing status. Healing has to be inferred from diagnosis codes, product application patterns, or the end of billing, all of which are indirect.
- Registries. Registries collect defined data elements with set endpoints, which gives depth and better comparability. Scale is limited by enrollment effort, and participating sites may not represent the broader market.
- Product utilization datasets. These track which products are applied to which wound types, in which settings, and over time. They are strong for market structure and weak for outcomes unless linked to clinical records.
The tradeoff is consistent: breadth comes at the cost of clinical granularity, and granularity comes at the cost of breadth. No single source gives you both without linkage or aggregation work, and that work introduces its own assumptions.
Care-setting coverage as a differentiator
Setting mix is the least visible weakness in many datasets. Sources built around hospital outpatient departments or academic centers under-represent skilled nursing facilities and home visits, even though a substantial share of CTP and CAMP application happens outside hospital-based wound centers. A dataset that omits those settings can misstate which products lead, which wound types dominate, and how outcomes look in the populations payers care about.
The Intellicure Wound Care Industry Dashboard is built on real-world data spanning SNFs, home visits, and hospital-based wound centers, with product tracking across CTPs, CAMPs, and wound types including DFUs, VLUs, and pressure ulcers. Confirm current dataset size, product counts, and date coverage on IntellicureAnalytics.ai before citing any figures, since scope changes as data is added.
What Can Real World Data Show That Clinical Trials Cannot?
Actual utilization versus assumed use
Trials test a product in the population its sponsor chose. RWD shows where it is used in practice: by wound type, wound stage, and care setting, and how that compares with the labeled or marketed indication. The commercial implication can be uncomfortable. A product positioned against one competitor in DFUs may, in practice, be applied mostly to VLUs or pressure ulcers in SNFs, where its real alternatives are different products or standard dressings. Competitive intelligence built on assumed use will aim at the wrong target.
Head-to-head comparison
Few RCTs compare one CTP against another directly. Sponsors generally test against standard of care, which leaves purchasers and clinicians without comparative evidence between the products they actually choose among. Observational comparative effectiveness studies can fill part of that gap, provided confounding is handled (see the next section). Any specific Intellicure comparative effectiveness result should be cited with its exact publication and year from the published research on IntellicureAnalytics.ai, and this article does not rely on unsourced figures.
Defensive and offensive uses
The defensive uses are about holding a position:
- Audit-ready evidence that documents how a product performs and is used in routine care.
- PMCF data that satisfies continuing clinical evaluation requirements.
- Support for coverage dialogue with MACs and payers who ask for evidence in the populations they cover.
The offensive uses are about finding position:
- Product ranking reports and leaderboards that show share and trajectory by wound type and setting.
- Trend analysis that reveals which categories are growing or contracting, and where.
- Identification of under-served indications or settings where a product is already gaining use informally.
Both uses depend on the same discipline: the data must be described accurately, including what it cannot establish.
What Are the Limitations and Biases of Real World Wound Data?
The central analytic problem is confounding by indication. Clinicians tend to reach for advanced products when standard care has failed or when a wound looks harder to heal. A raw comparison of healing rates between a CTP group and a standard dressing group can therefore show the advanced product performing worse, or the two looking equivalent, simply because the groups started with different prognoses. Adjustment is required: covariate control for wound size, duration, etiology, and comorbidity, and methods such as propensity score matching or weighting. Even then, unmeasured factors like perfusion, offloading adherence, and clinician judgment can remain.
Data quality problems specific to wounds
- Inconsistent measurement. Length-by-width by hand, tracing, and image-based methods give different areas, and technique varies by clinician and visit.
- Missing follow-up. Patients drop out of records when they transfer, are admitted, change settings, or die. If wounds that fail to heal are the ones most likely to disappear from view, healing rates are biased upward.
- Undefined endpoints. Complete closure, percent area reduction at four weeks, and time to healing are not interchangeable. A dataset that does not state which it uses, and how closure was confirmed, cannot be compared with trial results.
- Setting transitions. A patient who moves from a hospital wound center to a SNF may appear as two incomplete episodes unless records are linked.
Large N is not validity
A common misconception is that a large sample resolves these problems. It does not. More records narrow the statistical uncertainty around a number that may still be biased. Bias is a design and data problem, and scale can make a biased estimate look more precise.
RWD supports association, not causation. Studies that use it credibly are pre-specified: the question, population, exposure, outcome definition, and adjustment strategy are written down before the analysis, and methods are disclosed in enough detail for others to challenge them. Post hoc searching through subgroups until a favorable result appears is the practice that most damages the credibility of RWD with payers and reviewers.
How Do You Evaluate Whether a Wound Care Dataset Is Fit for Purpose?
Start with the dataset itself. A short checklist covers most of the risk:
- Wound type and product coverage: Are the wound etiologies and product categories you care about represented in meaningful volume?
- Care-setting mix: Are SNFs, home visits, and hospital-based centers all present, and in what proportions?
- Granularity: Is the data patient-level or aggregated? Aggregation limits adjustment and subgroup work.
- Time span: Is the window long enough to cover policy changes and product lifecycles?
- Endpoint definitions: Is healing defined, consistently applied, and documented?
- Update frequency: Is it current enough for the decision, especially for market tracking?
Match the dataset to the question
Different decisions need different properties. Market sizing and competitive analysis need utilization breadth across products and settings, and can tolerate aggregation. PMCF needs patient-level outcomes with consistent follow-up. A coverage submission needs methodological rigor, transparent adjustment, and ideally peer-reviewed publication, because reviewers discount unpublished internal analyses. A dataset excellent for one purpose can be inadequate for another.
Questions to put to a vendor
- How are healing outcomes defined, and who confirms them?
- How is missing data and loss to follow-up handled, and how much is there?
- Can the resulting work be published, and under what terms?
- What are the known gaps in settings, wound types, or time periods?
A vendor that answers the last question specifically is more trustworthy than one that says there are none.
When Should RWD Be Paired With Prospective Studies?
A workable decision rule: use RWD to generate hypotheses, estimate plausible effect size, and characterize real utilization. Move to a prospective or pragmatic study when the claim you want to make requires stronger causal evidence than an observational design can give, such as a new indication, a head-to-head superiority statement, or a payer requirement for controlled data. RWD also helps design that study, by showing realistic baseline healing rates and the patient mix a trial should reflect.
The two approaches are complementary rather than sequential. PMCF follow-up gathers structured outcomes from products already in use, while smaller, faster, lower-cost clinical trials can test specific questions that retrospective analysis raised. Intellicure offers PMCF services and clinical trial services alongside its dashboard and comparative effectiveness work, and none of these guarantees a particular result. Their value is in producing documented, methodologically transparent evidence, whatever it shows.
An illustrative workflow, not a specific case: a dashboard analysis shows that a product is used predominantly for pressure ulcers in SNFs, although its evidence base sits in DFUs. A comparative effectiveness study with pre-specified endpoints and adjustment tests how it performs against the alternatives actually used in that setting. The results are published, and the publication then supports conversations with payers and value analysis committees. Each step answers the limits of the one before it.
Matching Real World Data to the Decision It Has to Support
RWD earns its place when it is tied to a named decision: a coverage response, a PMCF plan, a competitive reassessment, or a trial design. It loses credibility when it is presented as proof of something its design cannot establish. State the limitations alongside the findings, define endpoints before the analysis, and choose the source for the question rather than the other way around.
If you are scoping a market analysis, the Wound Care Industry Dashboard is the practical starting point for utilization and trend questions. If the need is post-market evidence, a PMCF scoping conversation will clarify what data, follow-up, and endpoints the work requires. Learn more about our services.